Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

NIH-led clinical trial suggests that drug slows progression of rare neurological disease.

An experimental drug appears to slow the progression of Niemann-Pick disease type C1 (NPC1), a fatal neurological disease, according to results of a clinical study led by researchers at the National Institutes of Health. The study appears in The Lancet.

NPC1 is a rare genetic disorder that primarily affects children and adolescents, causing a progressive decline in neurological and cognitive functions. The U.S. Food and Drug Administration has not approved any treatments for the condition.

Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

Niemann-Pick disease type C1, a lipid storage disorder, as seen in a mouse cerebellum.

Read more View All News

This page was last updated on Friday, January 21, 2022